Overview

At GenScript, we have the technical means & experience to synthesize large numbers of challenging neoantigen peptides and provide tailored optimization tools for your downstream applications.

Stages of Neoantigen Precision Immunotherapy

GenScript’s Neoantigen Peptide Synthesis Service can be used for everything from functional screening of neoantigen candidates for TCR therapy to clinical stage vaccine immunogenicity testing.

Stages of Neoantigen Precision Immunotherapy

Tailored Synthesis For Any Application!

TCR-Antigen Affinity &
Immunogenicity
Screening
Personalized Cancer
Vaccine (PCV)
PCV Efficacy
Screening

Features of GenScript’s Service

Trustworthy Partner
in Neoantigen Synthesis
High Success Rate for
Synthesis of Difficult Peptides
Service Flexibility for
Personalized Therapy

"Reliable Reputation Amongst the Neoantigen Community"

"Screening hundreds of neoantigens in mice to validate the generalizability of SNP-7/8a was a tremendous undertaking that could not have been possible without the diligent efforts of GenScript's peptide chemists who were able to rapidly synthesize even the most challenging sequences at the high purity required."

―Geoffrey Lynn, Ph.D.
Avidea Technologies' CEO

Proven Reliability

Strong Application Expertise

Produced 1000’s of peptides for TCR therapy screening for 3T Biosciences

Synthesized Difficult peptides at varying amounts for Avidea’s novel SNAP PCV delivery system

Generated highly immunogenic peptides for DNA-based PCV efficacy screening

Track Record of Success

Track Record of Success

15 years of peptide synthesis production with a 98% success rate

Successful production of neoantigen peptides for the Top 50 immunotherapy companies and academic institutes

Continuous Communication

Global presence allowing for 24/7 communication and technical support

Project-specific managers and milestones

"Utilizing Reliable Synthesis Technologies & Tools for Superior Immunogenicity"

In 2019 GenScript manufactured 2500 neaontigen peptides with a 95% success rate using our tailored neoantigen peptide synthesis platform.

How Do We Do It?

Input EVERY

Step One: Input EVERY one of your peptides through our proprietary NeoPre™ bioinformatics algorithm to determine synthesis difficulty

Do you want to Know More About GenScript’s Neopre Bioinformatics Algorithm? Check out our Webpage for technologies for Difficult Neoantigen peptide Synthesis Here!

Peptide # Sequence Length Aggregation Hydrophobicity pI Synthetic Difficulty
Example 1 XXXXXXXX 25 4.18 -0.032 11.83 Middle
Example 1 XXXXXXXX 25 4.18 -0.032 11.83 Middle
Example 2 XXXXXXXX 25 31.63 0.49 10.06 Hard
Example 3 XXXXXXXX 25 -4.77 -0.58 6.78 Simple
pick the right synthesis platform to maximize success

Step Two: Based on difficulty and project details we help you pick the right synthesis platform to maximize success

Do you want to Know More About GenScript’s Unique Synthetic Methodologies for Difficult Neoantigen Peptide Synthesis and Purification? Check out our Webpage Here!

Technology Use Case
Microwave Automated, High Yield, Fast TAT
Liquid-Phase For modified peptides
Solid-Phase Higher purity peptides
 optimize any neoantigen sequence

Step Three: Once your peptides have been produced, GenScript offers library design tools to assist you optimize any neoantigen sequence

Library Use
Alanine Scanning Determine the most important individual amino acids
Overlapping Discover the perfect peptide length and sequence
T-Cell Truncation Identify the best epitope for a specific activity

"Reliable Peptide Yields In Your Timeline"

Neoantigens may require different yields, TAT, number, purity, ect, depending on their downstream application. To accommodate the needs of the neoantigen community, ALL of GenScript’s neoantigen peptide services are fully flexible and customizable.

Example Project 1: TCR Affinity and Immunogenicity Screening

GenScript offers a wide range of services to fit the needs of customers working on the beginning stages of T-cell therapy to clinical stage efficacy screening. Learn the various ways GenScript’s neoantigen peptide synthesis service can be customized to fit the peptide requirements of each phase, even including TCR affinity maturation and epitope identification! Read More »

Project Goal: Generate an Allogenic T-cell Therapy for Patient with Squamous Cell Carcinoma

Phase I: Phase I: After tumor biopsy and NGS, 300 different neoantigens were identified as possible candidates. These sequences were sent to GenScript to synthesize as a crude peptide library to be used for in-vitro functionality screening of TCR Binding Affinity and Efficacy.

# Peptides Analyzed # Peptides Synthesized Avg Peptide length Yield Purity TAT (B.D) Quality Control Synthesis Methods Used Delivery
300 290 30 AA 2 mg/peptide 70% 20 RP-HPLC
LC-MS
Simple: 68% of Peptides Synthesized Using Microwave Technology
Difficult: 22% of Peptides Synthesized Using LP/SP Manual technology
Lyophilized Peptides in Individual Aliquot Tubes

Phase II: In-vitro functionality screening identified a top candidate, however, in order to increase the binding affinity and efficacy of the TCR, researchers decided to design and generate an overlapping library to map the specific interaction between neoantigen epitope and TCR.

Library Type Length Offset Overlap # of Peptides Purity Yield Delivery Format
Overlapping 11 AA 3 AA 6 AA 100 80% 0.5 mg/peptide Pooling all quantity of partial peptides (20 peptides/pool)

Phase III: Once the specific epitope was identified, researchers designed and generated an alanine scanning library to determine which amino acids were most important for therapeutic efficacy, prior to affinity maturation of the TCR.

Library Type Length Purity Yield Delivery Format
Alanine Scanning 11 AA 98% 4 mg/peptide Lyophilized Peptides in Individual Aliquot Tubes (1 mg/tube)

Example Project 2: PCV Development

When generating a PCV, researchers require an array of peptide services due the specific needs of in vitro functionality screening, pre-clinical safety basement in laboratory models, and clinical efficacy analysis. Learn how GenScript’s neoantigen peptide synthesis service has flexible services which allow for reliable peptides for any phase of PCV development. Read More »

Project Goal: Generate a Personalized Cancer Vaccine for a patient with Glioblastoma

Phase I: After tumor biopsy and NGS, 150 different neoantigens were identified as possible candidates. These sequences were sent to GenScript to synthesize as a purified peptide library to be used for in-vitro functionality screening.

# Peptides Analyzed # Peptides Synthesized Avg Peptide length Yield Purity TAT (B.D) Quality Control Synthesis Methods Used Delivery
150 145 28 AA 2 mg/peptide 75% 20 RP-HPLC
LC-MS
Solubility Testing
Simple: 60% of Peptides Synthesized Using Microwave Technology
Difficult: 40% of Peptides Synthesized Using LP/SP Manual technology
Lyophilized Peptides in Individual Aliquot Tubes (1 mg/vial)

Phase II: In-vitro functionality screening identified 20 peptides for pre-clinical PCV development for non-human primate.

# Peptides Analyzed # Peptides Synthesized Avg Peptide length Yield Purity TAT (B.D) Quality Control Synthesis Methods Used Delivery
20 19 35 AA 500 mg/peptide 98% 30 RP-HPLC
LC-MS
Solubility Testing
Simple: 30% of Peptides Synthesized Using Microwave Technology
Difficult: 70% of Peptides Synthesized Using LP/SP Manual technology
Lyophilized Peptides in Individual Aliquot Tube

Phase III: After the vaccine was deemed “safe” through pre-clinical testing; the vaccine was used in a human patient. After inoculation, researchers required “vaccine” and “non-vaccine control” neoantigen peptides for clinical in-vitro efficacy screening of patient derived PBMC’s.

# Peptides Analyzed # Peptides Synthesized Avg Peptide length Yield Purity TAT (B.D) Quality Control Synthesis Methods Used Delivery
25 25 34 AA 14 mg/peptide 70% 20 RP-HPLC
LC-MS
Simple: 35% of Peptides Synthesized Using Microwave Technology
Difficult: 65% of Peptides Synthesized Using LP/SP Manual technology
Lyophilized Peptides in Individual Aliquot Tube (2 mg/vial)

Check Out GenScript’s Neoantigen Peptide Resources

REQUEST A QUOTE